MA49498A - Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant - Google Patents
Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenantInfo
- Publication number
- MA49498A MA49498A MA049498A MA49498A MA49498A MA 49498 A MA49498 A MA 49498A MA 049498 A MA049498 A MA 049498A MA 49498 A MA49498 A MA 49498A MA 49498 A MA49498 A MA 49498A
- Authority
- MA
- Morocco
- Prior art keywords
- diethylphenyl
- pyrazolo
- quinazoline
- carboxamide
- methoxyphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305826 | 2017-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49498A true MA49498A (fr) | 2021-05-26 |
Family
ID=59313166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049498A MA49498A (fr) | 2017-06-29 | 2018-06-28 | Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11160806B2 (fr) |
| EP (1) | EP3645535B1 (fr) |
| JP (1) | JP7141416B2 (fr) |
| KR (1) | KR102609333B1 (fr) |
| CN (1) | CN110896636B (fr) |
| AR (1) | AR112040A1 (fr) |
| AU (1) | AU2018293729B9 (fr) |
| BR (1) | BR112019027924A2 (fr) |
| CA (1) | CA3068357C (fr) |
| CL (1) | CL2019003848A1 (fr) |
| EA (1) | EA039764B1 (fr) |
| ES (1) | ES2900048T3 (fr) |
| IL (1) | IL271628B2 (fr) |
| MA (1) | MA49498A (fr) |
| PL (1) | PL3645535T3 (fr) |
| SG (1) | SG11201912651WA (fr) |
| TW (1) | TWI750393B (fr) |
| UY (1) | UY37778A (fr) |
| WO (1) | WO2019002454A1 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2303891T3 (en) | 2008-06-26 | 2016-05-30 | Servier Lab | PYRAZOLO-quinazolines as modulators of protein kinase-ACTIVITY |
-
2018
- 2018-06-21 UY UY0001037778A patent/UY37778A/es unknown
- 2018-06-28 SG SG11201912651WA patent/SG11201912651WA/en unknown
- 2018-06-28 JP JP2019572116A patent/JP7141416B2/ja active Active
- 2018-06-28 KR KR1020207002339A patent/KR102609333B1/ko active IP Right Grant
- 2018-06-28 PL PL18732820T patent/PL3645535T3/pl unknown
- 2018-06-28 US US16/624,488 patent/US11160806B2/en active Active
- 2018-06-28 WO PCT/EP2018/067394 patent/WO2019002454A1/fr unknown
- 2018-06-28 EP EP18732820.8A patent/EP3645535B1/fr active Active
- 2018-06-28 CN CN201880043442.0A patent/CN110896636B/zh active Active
- 2018-06-28 ES ES18732820T patent/ES2900048T3/es active Active
- 2018-06-28 EA EA202090115A patent/EA039764B1/ru unknown
- 2018-06-28 AR ARP180101781A patent/AR112040A1/es unknown
- 2018-06-28 AU AU2018293729A patent/AU2018293729B9/en active Active
- 2018-06-28 TW TW107122235A patent/TWI750393B/zh active
- 2018-06-28 MA MA049498A patent/MA49498A/fr unknown
- 2018-06-28 BR BR112019027924-5A patent/BR112019027924A2/pt unknown
- 2018-06-28 CA CA3068357A patent/CA3068357C/fr active Active
-
2019
- 2019-12-22 IL IL271628A patent/IL271628B2/en unknown
- 2019-12-26 CL CL2019003848A patent/CL2019003848A1/es unknown
-
2021
- 2021-09-30 US US17/490,318 patent/US20220016122A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11160806B2 (en) | 2021-11-02 |
| CL2019003848A1 (es) | 2020-07-10 |
| KR20200020905A (ko) | 2020-02-26 |
| CN110896636B (zh) | 2022-07-19 |
| EA039764B1 (ru) | 2022-03-11 |
| IL271628B1 (en) | 2023-03-01 |
| BR112019027924A2 (pt) | 2020-08-18 |
| IL271628A (en) | 2020-02-27 |
| AR112040A1 (es) | 2019-09-11 |
| UY37778A (es) | 2019-01-31 |
| TWI750393B (zh) | 2021-12-21 |
| CN110896636A (zh) | 2020-03-20 |
| KR102609333B1 (ko) | 2023-12-01 |
| ES2900048T3 (es) | 2022-03-15 |
| US20220016122A1 (en) | 2022-01-20 |
| AU2018293729A1 (en) | 2020-01-23 |
| JP2020525477A (ja) | 2020-08-27 |
| AU2018293729B2 (en) | 2022-03-10 |
| AU2018293729B9 (en) | 2022-07-14 |
| EP3645535B1 (fr) | 2021-09-08 |
| CA3068357A1 (fr) | 2019-01-03 |
| EA202090115A1 (ru) | 2020-05-25 |
| EP3645535A1 (fr) | 2020-05-06 |
| SG11201912651WA (en) | 2020-01-30 |
| PL3645535T3 (pl) | 2022-03-21 |
| WO2019002454A1 (fr) | 2019-01-03 |
| US20200246339A1 (en) | 2020-08-06 |
| IL271628B2 (en) | 2023-07-01 |
| CA3068357C (fr) | 2022-04-19 |
| TW201904971A (zh) | 2019-02-01 |
| JP7141416B2 (ja) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| EA201990519A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| EA201891099A1 (ru) | 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 | |
| MX2018002017A (es) | Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina. | |
| WO2018045276A8 (fr) | Stimulateurs sgc bicycliques fusionnés | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| EA202090371A1 (ru) | 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET | |
| EA201591255A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| WO2014027975A3 (fr) | Nouvelles formulations pharmaceutiques administrées par voie orale | |
| HK1247203A1 (zh) | 取代的咪唑並[1，2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法 | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| WO2016010869A3 (fr) | Composés de quinoléine fusionnés utilisés comme inhibiteurs de la voie de signalisation pi3k/mtor | |
| EA201591904A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK | |
| EA201790179A1 (ru) | [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний | |
| EA201690100A1 (ru) | Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин | |
| WO2014027981A3 (fr) | Formulations de comprimés effervescents de dapoxétine et d'un inhibiteur de pde5 | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
| MA49498A (fr) | Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant | |
| IL265153A (en) | 8-(azetidin-1-yl)-[4,2,1]triazolo[5,1-a]pyridinyl compounds, preparations and methods of use |